6:15 PM
 | 
Dec 18, 2012
 |  BC Extra  |  Clinical News

Vanda gains on Phase III sleep disorder data

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) jumped $0.61 (19%) to $3.83 on Tuesday after oral tasimelteon met the co-primary endpoints in the 84-patient Phase III SET trial to treat non-24-hour...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >